Shots:

• The companies collaborated to advance the development of the RP2/3 program in CRC & HCC
• The companies will share costs to develop RP3 with Roche's Tecentriq & Avastin for 2L HCC and 3L CRC & also combined RP3 for 1L HCC & RP2 for 3L CRC. Replimune will lead the operationalization of the clinical trial
• The P-II program of RP2/3 is expected to be initiated in H1’23 while P-II trials for SCCHN, HCC & CRC are also included in the program. The goal of RP2/3 is to deliver CD40L & 4-1BBL proteins in a targeted and powerful manner to the tumor & draining lymph nodes which are the sites of immune response initiation & aim for systemic immune-based efficacy on tumors & reducing off-target toxicity

Ref: Globenewswire | Image: Roche